[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100479920":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":44,"centralContacts":49,"locations":58,"responsibleParty":274,"collaborators":28,"id":276,"slug":277,"hasResults":278,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":278,"sex":284,"minAge":285,"maxAge":28,"enrollmentInfo":286,"targetDuration":28,"studyType":289,"phases":290,"briefSummary":292,"conditions":293,"keywords":296,"overallStatus":77,"whyStopped":28,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":320},{"fullName":5,"class":6},"Centre Leon Berard","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"ARM A","EXPERIMENTAL","RADIOTHERAPY boost 20 to 30 Gy on lymph nodes",[13],"Radiation: Radiotherapy boost",{"label":15,"type":10,"description":16,"interventionNames":17},"ARM B","One cycle of CARBOPLATIN AUC7",[18],"Drug: Carboplatin AUC7",{"label":20,"type":6,"description":21,"interventionNames":22},"ARM C","3 cycles of ETOPOSIDE and CISPLATIN",[23],"Drug: 3 cycles of EP",{"label":25,"type":26,"description":27,"interventionNames":28},"OBSERVATIONAL COHORT","NO_INTERVENTION","STANDARD RADIOTHERAPY on lymph nodes",null,[30,35,40],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":28},"RADIATION","Radiotherapy boost","Radiotherapy boost 20 to 30 Gy, in daily 2 Gy fractions and 5 fractions per week :\n\n* 20 Gy if no more disease is visible (node \\\u003C 1 cm in large diameter)\n* 24 Gy for nodes \\\u003C= 2 cm\n* 30 Gy for nodes \\> 2 cm",[9],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":28},"DRUG","Carboplatin AUC7","Carboplatin at dose (mg) = AUC7 (mg\u002Fml x min) x (DFG ml\u002Fmin + 25)",[15],{"type":36,"name":41,"description":42,"armGroupLabels":43,"otherNames":28},"3 cycles of EP","3 Cycles of EP chemotherapy, administred every 3 weeks following standard practice",[20],[45],{"name":46,"affiliation":47,"role":48},"Aude FLECHON, Dr","Centre Leon Berard (Lyon, France)","PRINCIPAL_INVESTIGATOR",[50,55],{"name":51,"role":52,"phone":53,"phoneExt":28,"email":54},"Ellen BLANC","CONTACT","+33 4 78 78 29 67","ellen.blanc@lyon.unicancer.fr",{"name":46,"role":52,"phone":56,"phoneExt":28,"email":57},"+ 33 4 78 78 26 43","aude.flechon@lyon.unicancer.fr",[59,75,88,100,112,127,141,154,172,186,202,216,228,246,262],{"facility":60,"status":61,"city":62,"state":28,"zip":28,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"CHU Besançon","NOT_YET_RECRUITING","Besançon","France","FR",{"type":66,"coordinates":67},"Point",[68,69],6.01815,47.24878,{"lat":69,"lon":68},[72],{"name":73,"role":52,"phone":28,"phoneExt":28,"email":74},"Elodie KLAJER","elodie.klajer@gmail.com",{"facility":76,"status":77,"city":78,"state":28,"zip":28,"country":63,"countryCode":64,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"CHU Bordeaux","RECRUITING","Bordeaux",{"type":66,"coordinates":80},[81,82],-0.58046,44.84124,{"lat":82,"lon":81},[85],{"name":86,"role":52,"phone":28,"phoneExt":28,"email":87},"Marine GROSS-GOUPIL","marine.gross-goupil@chu-bordeaux.fr",{"facility":89,"status":77,"city":90,"state":28,"zip":28,"country":63,"countryCode":64,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Centre François Baclesse","Caen",{"type":66,"coordinates":92},[93,94],-0.35912,49.18585,{"lat":94,"lon":93},[97],{"name":98,"role":52,"phone":28,"phoneExt":28,"email":99},"Florence JOLY","f.joly@baclesse.unicancer.fr",{"facility":101,"status":77,"city":102,"state":28,"zip":28,"country":63,"countryCode":64,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Centre Jean Perrin","Clermont-Ferrand",{"type":66,"coordinates":104},[105,106],3.08682,45.77969,{"lat":106,"lon":105},[109],{"name":110,"role":52,"phone":28,"phoneExt":28,"email":111},"Hakim MAHAMMEDI","hakim.mahammedi@clermont.unicancer.fr",{"facility":113,"status":77,"city":114,"state":28,"zip":28,"country":63,"countryCode":64,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Centre Oscar Lambret","Lille",{"type":66,"coordinates":116},[117,118],3.05512,50.63391,{"lat":118,"lon":117},[121,124],{"name":122,"role":52,"phone":28,"phoneExt":28,"email":123},"Thomas RYCKEWAERT","t-ryckewaert@o-lambret.fr",{"name":125,"role":126,"phone":28,"phoneExt":28,"email":28},"Aurélien CARNOT","SUB_INVESTIGATOR",{"facility":128,"status":77,"city":129,"state":28,"zip":28,"country":63,"countryCode":64,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"CHU de Limoges","Limoges",{"type":66,"coordinates":131},[132,133],1.24759,45.83362,{"lat":133,"lon":132},[136,139],{"name":137,"role":52,"phone":28,"phoneExt":28,"email":138},"Julia PESTRE MUNIER","julia.munier-pestre@chu-limoges.fr",{"name":140,"role":126,"phone":28,"phoneExt":28,"email":28},"Valérie LE BRUN-LY",{"facility":142,"status":77,"city":143,"state":28,"zip":28,"country":63,"countryCode":64,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Centre Leon Bérard","Lyon",{"type":66,"coordinates":145},[146,147],4.84789,45.74906,{"lat":147,"lon":146},[150,152],{"name":151,"role":52,"phone":28,"phoneExt":28,"email":57},"Aude FLECHON",{"name":153,"role":126,"phone":28,"phoneExt":28,"email":28},"Armelle VINCENEUX",{"facility":155,"status":77,"city":156,"state":28,"zip":28,"country":63,"countryCode":64,"cosmosGeoPoint":157,"geoPoint":161,"contacts":162},"Institut Paoli Calmettes","Marseille",{"type":66,"coordinates":158},[159,160],5.38107,43.29695,{"lat":160,"lon":159},[163,166,168,170],{"name":164,"role":52,"phone":28,"phoneExt":28,"email":165},"Gwenaëlle GRAVIS","gravisg@ipc.unicancer.fr",{"name":167,"role":126,"phone":28,"phoneExt":28,"email":28},"Slimane DERMECHE",{"name":169,"role":126,"phone":28,"phoneExt":28,"email":28},"Mathilde GUERIN",{"name":171,"role":126,"phone":28,"phoneExt":28,"email":28},"Cécile VICIER",{"facility":173,"status":77,"city":174,"state":28,"zip":28,"country":63,"countryCode":64,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"Centre Antoine Lacassagne","Nice",{"type":66,"coordinates":176},[177,178],7.26608,43.70313,{"lat":178,"lon":177},[181,184],{"name":182,"role":52,"phone":28,"phoneExt":28,"email":183},"Agnès DUCOULOMBIER","agnes.ducoulombier@nice.unicancer.fr",{"name":185,"role":126,"phone":28,"phoneExt":28,"email":28},"Delphine BORCHIELLINI",{"facility":187,"status":61,"city":188,"state":28,"zip":28,"country":63,"countryCode":64,"cosmosGeoPoint":189,"geoPoint":193,"contacts":194},"Hôpital Saint Louis","Paris",{"type":66,"coordinates":190},[191,192],2.3488,48.85341,{"lat":192,"lon":191},[195,198,200],{"name":196,"role":52,"phone":28,"phoneExt":28,"email":197},"Stéphane CULINE","stephane.culine@sls.aphp.fr",{"name":199,"role":126,"phone":28,"phoneExt":28,"email":28},"Clément DUMONT",{"name":201,"role":126,"phone":28,"phoneExt":28,"email":28},"Tiphaine LAMBERT",{"facility":203,"status":77,"city":204,"state":28,"zip":28,"country":63,"countryCode":64,"cosmosGeoPoint":205,"geoPoint":209,"contacts":210},"ICO René Gauducheau","Saint-Herblain",{"type":66,"coordinates":206},[207,208],-1.651,47.21154,{"lat":208,"lon":207},[211,214],{"name":212,"role":52,"phone":28,"phoneExt":28,"email":213},"Emmanuelle BOMPAS","emmanuelle.bompas@ico.unicancer.fr",{"name":215,"role":126,"phone":28,"phoneExt":28,"email":28},"Frédéric ROLLAND",{"facility":217,"status":61,"city":218,"state":28,"zip":28,"country":63,"countryCode":64,"cosmosGeoPoint":219,"geoPoint":223,"contacts":224},"Hôpital Foch","Suresnes",{"type":66,"coordinates":220},[221,222],2.22929,48.87143,{"lat":222,"lon":221},[225],{"name":226,"role":52,"phone":28,"phoneExt":28,"email":227},"Christine ABRAHAM","c.abraham@hopital-foch.com",{"facility":229,"status":77,"city":230,"state":28,"zip":28,"country":63,"countryCode":64,"cosmosGeoPoint":231,"geoPoint":235,"contacts":236},"Institut Universitaire de Cancer de Toulouse (IUCT-O)","Toulouse",{"type":66,"coordinates":232},[233,234],1.44367,43.60426,{"lat":234,"lon":233},[237,240,242,244],{"name":238,"role":52,"phone":28,"phoneExt":28,"email":239},"Christine CHEVREAU","chevreau.christine@iuct-oncopole.fr",{"name":241,"role":126,"phone":28,"phoneExt":28,"email":28},"Thibaud VALENTIN",{"name":243,"role":126,"phone":28,"phoneExt":28,"email":28},"Loïc MOUREY",{"name":245,"role":126,"phone":28,"phoneExt":28,"email":28},"Damien POUESSEL",{"facility":247,"status":61,"city":248,"state":28,"zip":28,"country":63,"countryCode":64,"cosmosGeoPoint":249,"geoPoint":253,"contacts":254},"Institut de Cancérologie de Lorraine","Vandœuvre-lès-Nancy",{"type":66,"coordinates":250},[251,252],6.17114,48.66115,{"lat":252,"lon":251},[255,258,260],{"name":256,"role":52,"phone":28,"phoneExt":28,"email":257},"Lionel GEOFFROIS","l.geoffrois@nancy.unicancer.fr",{"name":259,"role":126,"phone":28,"phoneExt":28,"email":28},"Camille SIMON",{"name":261,"role":126,"phone":28,"phoneExt":28,"email":28},"Vincent MASSART",{"facility":263,"status":77,"city":264,"state":28,"zip":28,"country":63,"countryCode":64,"cosmosGeoPoint":265,"geoPoint":269,"contacts":270},"Institut Gustave Roussy","Villejuif",{"type":66,"coordinates":266},[267,268],2.35992,48.7939,{"lat":268,"lon":267},[271],{"name":272,"role":52,"phone":28,"phoneExt":28,"email":273},"Pierre BLANCHARD","pierre.blanchard@gustaveroussy.fr",{"type":275,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100479920","phase-2-de-escalation-study-for-stage-iiaiib--3-cm-seminoma-100479920",false,"NCT05529251","De-escalation Study for Stage IIa\u002FIIb \u003C 3 cm Seminoma","Prospective Therapeutic De-escalation and miRNA-M371 Biomarker Evaluation Phase II Study for Stage IIa\u002FIIb \u003C 3 cm Seminomas","EDEN","Inclusion criteria :\n\n1. Age ≥ 18 years on the day of signing informed consent.\n2. Primary testicular seminomatous germ cell tumor.\n3. Stage IIa\u002FIIb \\\u003C 3 cm in largest diameter seminoma, histologically proved after orchiectomy.\n4. Confirmation of a progressive disease (positive PET scan or increase of lymph nodes size by two successive CT scan).\n5. Good prognosis according to IGCCCG and LDH \\\u003C 2.5 x Upper Limit of Normal (ULN).\n6. Normal alpha-fetoprotein (AFP) before and after orchiectomy.\n7. No prior treatment with radiotherapy or chemotherapy.\n8. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2.\n9. Adequate bone-marrow, hepatic, and renal functions with:\n\n   * Neutrophils ≥ 1.5 x Giga\u002Fl, platelets ≥ 100 x Giga\u002Fl,\n   * Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 1,5 x ULN,\n   * Serum creatinine \\\u003C 140 µmol\u002Fl OR calculated clearance \\> 60 ml\u002Fmin (using either Cockcroft-Gault formula or Modification of Diet in Renal Disease (MDRD) for \\> 65 years old),\n   * Direct and total bilirubin ≤ ULN.\n10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.\n11. Accepting to use effective contraceptive measures or abstain from heterosexual activity, for the course of the study and through 12 months after the last dose of chemotherapy or being surgically sterile. All patients should seek advice regarding cryoconservation of sperm prior treatment initiation because of the possibility of infertility\n12. Affiliation to a health insurance.\n13. Signed and dated informed consent.\n\nNon-exclusion criteria :\n\n1. Extra-retroperitoneal metastasis on Computed tomography scan (CT scan).\n2. Infection by Human Immunodeficiency Virus (HIV), or active infection with the Hepatitis B or C virus.\n3. History, within 2 years, of cancer other than seminoma, except for treated skin cancer (basal cell).\n4. Uncontrolled or severe cardiovascular pathology.\n5. Uncontrolled or severe hepatic pathology.\n6. Patient deprived of liberty or requiring tutorship or curatorship.\n7. Psychological, physical, sociological, or geographical conditions that would limit compliance with study protocol requirements (at the investigator's discretion).\n8. Participation to another clinical trial, except for supportive care trials.","MALE","18 Years",{"count":287,"type":288},90,"ESTIMATED","INTERVENTIONAL",[291],"PHASE2","Phase II, multicenter, prospective, randomized, non-comparative, de-escalation study.\n\nPatients with stage IIa\u002FIIb \\\u003C 3 cm seminoma histologically proved after orchiectomy will be included in the study and will receive 1 cycle of Etoposide Cisplatine (EP) chemotherapy.\n\nPatients with negative week-3 PET-scan after the EP cycle, will be randomized (1:1 ratio, stratification according to the disease stage (stage IIa versus IIb seminoma)) to receive either radiotherapy (RT) boost on lymph nodes or 1 cycle of carboplatin AUC7 chemotherapy.\n\nPatients with positive week-3 PET-scan will received 3 additional cycles of EP chemotherapy.\n\nIn parallel, eligible patients scheduled to receive standard lombo-aortic RT will be registered in an observational cohort.",[294,295],"Seminoma","Stage II",[297,298,299,300,301,302,303,304,305,306,307,308,309,310],"De-escalation","Chemotherapy","Radiotherapy","Carboplatin","Etoposide","Cisplatine","Micro-RNA-M371","PET scan","Overall survival","Biomarker","Efficacy","Progression free rate","Safety","Quality of life","2024-01-24",{"date":313,"type":314},"2024-01-25","ACTUAL",{"date":316,"type":314},"2022-09-06",{"date":318,"type":288},"2030-09-06",{"name":5,"class":6},15]